Borderline resectable pancreatic cancer: On the edge of survival

Cancer Control

Volumn 15, Issue 4, 2008, Pages 295-307

  Springett, Gregory M ^a   Hoffe, Sarah E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; PACLITAXEL; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANOREXIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEALTH PROGRAM; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS CANCER; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PNEUMONIA; RASH; REVIEW; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TRANSAMINITIS; TUMOR VOLUME; ULCER;

EID: 55249124549     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480801500404     Document Type: Review

References (63)

1. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13(8):1035-1046. Epub 2006 Jul 24.
2. Quiros RM, Brown KM, Hoffman JP, et al. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007;25(4):267-273.
3. NCCN practice guidelines for pancreatic cancer. Oncology (Williston Park). 1997;11(11A):41-55.
4. Yendluri V, Centeno B, Springett GM, et al. Pancreatic cancer presenting as a Sister Mary Joseph's nodule: case report and update of the literature. Pancreas. 2007;34(1):161-164.
5. Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2001;5(1):27-35.
6. Valls C, Andía E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol. 2002;178(4):821-826.
7. Legmann P, Vignaux O, Dousset B, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol. 1998;170(5):1315-1322.
8. DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004;141(10):753-763.
9. Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20(2):227-251.
10. Farma JM, Melis M, Santillan A, et al. Positron emission tomography/ computed tomography fusion scans enhances preoperative treatment planning in patients with pancreatic cancer. In: Proceedings from the 61st Annual Society of Surgical Oncology Meeting; March 13-16, 2008; Chicago, IL. Abstract 10.
11. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008 Jun 13. Epub ahead of print.
12. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168(6):1439-1443.
13. Schima W, Ba-Ssalamah A, Kölblinger C, et al. Pancreatic adenocarcinoma. Eur Radiol. 2007;17(3):638-649. Epub 2006 Oct 5.
14. Hough TJ, Raptopoulos V, Siewert B, et al. Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas. AJR Am J Roentgenol. 1999;173(6):1509-1512.
15. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980;46(9):1945-1949.
16. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705-1710.
17. Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer. 1988;61(6):1110-1116.
18. Raben A, Mychalczak B, Brennan MF, et al. Feasibility study of the treatment of primary unresectable carcinoma of the pancreas with 103Pd brachytherapy. Int J Radiat Oncol Biol Phys. 1996;35(2):351-356.
19. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335-1339.
20. Jessup JM, Steele G Jr, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993;128(5):559-564.
21. Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg. 1995;169(1):71-77; discussion 77-78.
22. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16(1):317-323.
23. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: an outcomes trial. Cancer. 2000;89(2):314-327.
24. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13(9):1201-1208. Epub 2006 Sep 6.
25. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8(10):758-765.
26. Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006;13(1):66-74. Epub 2006 Jan 1.
27. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
28. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34(4):867-872.
29. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs. 1996;14(3):257-263.
30. McGinn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys. 2003;56(4 suppl):10-15.
31. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 2002;52(5):1293-1302.
32. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19(22):4202-4208.
33. Wilkowski R, Thoma M, Schauer R, et al. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28(10):1011-1018. Epub 2004 Sep 29.
34. Safran H, Dipetrillo T, Iannitti D, et al. Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol Biol Phys. 2002;54(1):137-141.
35. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633; discussion 633-636.
36. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 3: update on 5-year survival. J Gastrointest Surg. 2005;9(9):1191-1204; discussion 1204-1206.
37. Brown MW, Ning H, Arora B, et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2006;65(1):274-283.
38. Bryan PJ, Custar S, Haaga JR, et al. Respiratory movement of the pancreas: an ultrasonic study. J Ultrasound Med. 1984;3(7):317-320.
39. Bussels B, Goethals L, Feron M, et al. Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol. 2003;68(1):69-74.
40. Bhasin DK, Rana SS, Jahagirdar S, et al. Does the pancreas move with respiration? J Gastroenterol Hepatol. 2006;21(9):1424-1427.
41. Gierga DP, Brewer J, Sharp GC, et al. The correlation between internal and external markers for abdominal tumors: implications for respiratory gating. Int J Radiat Oncol Biol Phys. 2005;61(5):1551-1558. Erratum in: Int J Radiat Oncol Biol Phys. 2005;62(4):1257.
42. Shirato H, Shimizu S, Kunieda T, et al. Physical aspects of a realtime tumor-tracking system for gated radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(4):1187-1195.
43. Eccles C, Brock KK, Bissonnette JP, et al. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64(3):751-759.
44. Kini VR, Vedam SS, Keall PJ, et al. Patient training in respiratory-gated radiotherapy. Med Dosim. 2003;28(1):7-11.
45. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1017-1021.
46. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63(2):320-323.
47. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110(1):47-55.
48. Fogelman DR, Schreibman S, Sherman W, et al. Neoadjuvant GTX and radiation for unresectable pancreatic cancer: a prospective phase II trial. In: Proceedings from the 4th Annual Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 143.
49. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008;61(1):167-175. Epub 2007 Apr 18.
50. Landry J, Catalano P, Hoffman J, et al. ECOG 1200: a randomized phase II trial of gemcitabine plus radiotherapy vs gemcitabine, 5-fluorouracil and cisplatin followed by radiotherapy and 5-fluorouracil in patients with locally advanced, potentially resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):S272. Abstract 2111.
51. Heinrich S, Pestalozzi BC, Schäfer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526- 2531.
52. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. Epub 2007 Apr 23.
53. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567-578.
54. Sartor CI. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nat Clin Pract Oncol. 2004;1(2):80-87.
55. Kortmansky JS, O'Reilly EM, Minsky BD, et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings. 2005;23(16S, Part I of II June 1 Suppl):4107. Abstract.
56. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol. 2005;28(6):570-575.
57. Krempien R, Muenter MW, Huber PE, et al. Randomized phase II: study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer. PARC: study protocol [ISRCTN56652283]. BMC Cancer. 2005;5:131.
58. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology. 2005;69(suppl 3):46-56. Epub 2005 Nov 21.
59. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13(11):3395-3402.
60. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145-147. Epub 2004 Jan 25.
61. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006;24(7):1145-1151.
62. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004;22(4):592-601. Epub 2004 Jan 15.
63. Posner M, Chang KJ, Rosemurgy A, et al. Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S June 20 suppl):4518. Abstract.